idelalisib (zydelig) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Fast Track FDA Accelerated Approval FDA

Active Ingredient History

  • Now
Idelalisib is a first-in-class selective inhibitor of adenosine-5'-triphosphate (ATP) binding to PI3Kdelta kinase, resulting in inhibition of the P13K signalling pathway in malignant B cells. The compound is approved for the treatment of several types of blood cancer. Idelalisib is intended to be used in combination with rituximab as second or subsequent line therapy for the treatment of chronic lymphocytic leukaemia. The drug may cause fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation.   NCATS

  • SMILES: CC[C@H](NC1=NC=NC2=C1N=CN2)C3=NC4=C(C(=O)N3C5=CC=CC=C5)C(F)=CC=C4
  • Mol. Mass: 415.423
  • ALogP: 3.75
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)


More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

5-fluoro-3-phenyl-2-[(1s)-1-(3h-purin-6-ylamino)propyl]quinazolin-4(3h)-one | 5-fluoro-3-phenyl-2-((s)-1-(9h-purin-6-ylamino)-propyl)-3h-quinazolin-4-one | cal101 | cal 101 | cal-101 | gs-1101 | gs-11cal-101 | idelalisib | idelaslisib | zydelig


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue